Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.

Haque M, Li J, Huang YH, Almowaled M, Barger CJ, Karpf AR, Wang P, Chen W, Turner SD, Lai R.

Cancers (Basel). 2019 Aug 6;11(8). pii: E1119. doi: 10.3390/cancers11081119.


Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma.

Huang YH, Vakili MR, Molavi O, Morrissey Y, Wu C, Paiva I, Soleimani AH, Sanaee F, Lavasanifar A, Lai R.

Cancers (Basel). 2019 Feb 20;11(2). pii: E248. doi: 10.3390/cancers11020248.


Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model.

Huang YH, Molavi O, Alshareef A, Haque M, Wang Q, Chu MP, Venner CP, Sandhu I, Peters AC, Lavasanifar A, Lai R.

Cancers (Basel). 2018 Jun 16;10(6). pii: E206. doi: 10.3390/cancers10060206.


Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.

Wu C, Gupta N, Huang YH, Zhang HF, Alshareef A, Chow A, Lai R.

BMC Cancer. 2018 Apr 2;18(1):361. doi: 10.1186/s12885-018-4300-2.


Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.

Soleimani AH, Garg SM, Paiva IM, Vakili MR, Alshareef A, Huang YH, Molavi O, Lai R, Lavasanifar A.

Drug Deliv Transl Res. 2017 Aug;7(4):571-581. doi: 10.1007/s13346-017-0369-4.


A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.

Wu C, Zhang HF, Gupta N, Alshareef A, Wang Q, Huang YH, Lewis JT, Douglas DN, Kneteman NM, Lai R.

J Hematol Oncol. 2016 Nov 8;9(1):120.


The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.

Alshareef A, Zhang HF, Huang YH, Wu C, Zhang JD, Wang P, El-Sehemy A, Fares M, Lai R.

Sci Rep. 2016 Sep 19;6:33710. doi: 10.1038/srep33710.

Supplemental Content

Loading ...
Support Center